Profile for Singapore Patent: 10202007759R

US Patent Family Members and Approved Drugs for Singapore Patent: 10202007759R

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Oct 21, 2035	Eisai Inc	DAYVIGO	lemborexant
	Oct 21, 2035	Eisai Inc	DAYVIGO	lemborexant
	Oct 21, 2035	Eisai Inc	DAYVIGO	lemborexant

Key insights for pharmaceutical patentability - Singapore patent SG10202007759R

Last updated: April 28, 2026

What does Singapore drug patent SG10202007759R cover, and how does it sit in the SG patent landscape?

SG10202007759R is a Singapore patent publication covering a drug-related subject matter tied to an identified invention claimed in the Singapore record. A full, precise analysis of its claim-by-claim scope, the exact active ingredient(s), salt/polymorph, formulation, method-of-treatment, and priority/entitlement positions cannot be produced from the information available in this session.

No dataset or bibliographic text for SG10202007759R (title, assignee, inventors, priority application numbers/dates, International Patent Classification, abstract, full claims, prosecution history, or legal status) is present here. Under the operating constraints, an incomplete claim analysis would be non-actionable, so no substantive scope or landscape breakdown is provided.

Is SG10202007759R part of a “new chemical entity” or a later-life cycle asset?

Not determinable from the available record in this session.

What are the independent and dependent claims for SG10202007759R?

Not determinable from the available record in this session.

What is the priority chain and likely claim construction triggers (salt, polymorph, regimen, patient subgroup)?

Not determinable from the available record in this session.

How does SG10202007759R overlap with other Singapore filings (same compound, same formulation, same method-of-use)?

Not determinable from the available record in this session.

What is the enforcement posture (grant status, term status, disclaimers, amended claims, lapsed/active)?

Not determinable from the available record in this session.

---

What can be concluded with certainty right now

• The identifier SG10202007759R refers to a Singapore patent record, but this session contains no accessible bibliographic text or claim set needed to map scope, claim breadth, or landscape overlap.
• Producing a “detailed analysis” without the claim text and publication metadata would produce errors or inventions of facts, which the constraints prohibit.

---

Key Takeaways

• Claim scope and patent-landscape overlap for SG10202007759R cannot be accurately analyzed without the actual Singapore publication/claims text and bibliographic metadata.
• A business-grade landscape requires the claim set, priority chain, and legal status; none are available in this session.

---

FAQs

1. What is SG10202007759R’s drug substance or formulation scope?
   Not determinable from the available information in this session.

2. Does SG10202007759R claim a compound, a formulation, or a method of treatment?
   Not determinable from the available information in this session.

3. What are the independent claim elements that define infringement risk?
   Not determinable from the available information in this session.

4. Which other Singapore patents likely cover the same asset (compound or regimen)?
   Not determinable from the available information in this session.

5. Is the patent granted and in-force, or only published/expired?
   Not determinable from the available information in this session.

---

References

No sources were cited because no SG10202007759R claim text or publication metadata is available in this session.